Overview

Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty

Status:
Unknown status

Trial end date:
2019-07-30

Target enrollment:
0

Participant gender:
All

Summary

This study will examine the efficacy of Liposomal Bupivacaine (Exparel) in hip fracture patients undergoing hip hemiarthroplasty for femoral neck fractures through a posterior approach. Post-operative measures will be assessing pain, overall opiate use, delirium, time-to-ambulation and discharge status.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Maimonides Medical Center

Treatments:

Bupivacaine

Criteria

Inclusion Criteria:

Men and women sixty-five years of age and older with isolated intracapsular hip fractures
undergoing hemi arthroplasty through a posterior approach with the ability to consent to
the study.

Exclusion Criteria:

Under sixty-five years of age, extracapsular hip fracture, suffer from any form of
cognitive compromise that leaves them unable to consent, or if they are treated with any
surgical modality other than hip hemiarthroplasty.